Due to persistent viremia, worsening kidney parameters, high suspicion of RPGN secondary to HBV-associated IgA, and high probability of resistance to entecavir, the antiviral medication was switched to tenofovir disoproxil fumarate with a renally adjusted dosage of 300 mg every three days. The gene discussed is CD79A; the disease is rapidly progressive glomerulonephritis.